PROS1 and End Stage Liver Disease: However, it appears likely that our data also reflect unequal kinetics of the changes of coagulation factors and natural anticoagulants during the course of liver cirrhosis, as for example the activity of protein S appears to be largely unaffected even in patients with end stage liver disease (Fig 1).